Gabapentin for the Treatment of Neuroleptic-Induced Tremor

A 4 Week, Parallel-Design, Double-Blind, Placebo-Controlled Trial of Gabapentin in the Treatment of Neuroleptic-Induced Tremor: Clinical and Instrumental Ratings of Outcome.

Status

Terminated

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00533455

Enrollment

Registered

2007-09-21

Start date

2004-03-31

Completion date

2007-08-31

Last updated

2007-09-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Neuroleptic-Induced Tremor

Keywords

Antipsychotics, tremor

Brief summary

We will attempt to establish whether gabapentin as compared with placebo will reduce the severity of tremors caused by the use of antipsychotic medications. Baseline severity of tremor will be measured using both clinical ratings and ratings obtained with an instrument designed to measure tremor, giving more objective evidence of tremor frequency and severity.

Detailed description

We propose to enroll 40 veterans with antipsychotic induced tremor in this RCT of gabapentin. Baseline measurements will be obtained with the tremor section of the UPDRS, the Simpson-Angus Scale, the ESRS, AIMS, and the Barnes Akathisia SScale. The Tremorometer, an instrument designed to quantatatively measure frequency, amplitude, and tremor power will be used for baseline and subsequent assessments. Demographic data will be collected. Diagnoses will be established with the SCID. Appropriate lab studies with an EKG will be done at baseline and at study end. Patients will be randomized to gabapentin or placebo and assessed on a blinded basis. Effectiveness of the blind will be assessed at study end. Gabapentin will be started at 300 mg/day and tapered up to a maximum of 1800 mg/day. The SF36 will be used to assess quality of life.

Interventions

DRUGGabapentin

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Masking

DOUBLE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Veterans 18 and older with an observable tremor judged to be caused by exposure to antipsychotics

Exclusion criteria

* Concomitant use of other anticonvulsants, L-Dopa, cocaine, amphetamines, or other tremorogenic agents excepting SSRIs, TCAs. * Current suicidality, severe psychosis, inability to sign informed consent or to cooperate with study procedures. * Current use of gabapentin or exposure to gabapentin in the past 2 years. * Women who are pregnant, or not using adequate birth control.

Design outcomes

Primary

Measure	Time frame
Reduction of tremor on the UPDR and SAS	—
Reduction of instrumental measurements of percent tremor and tremor power.	—

Secondary

Measure	Time frame
Reduction of rigidity, bradykinesia, dyskinesia	—
Improvement in quality of life	—

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026